O
OncoDNA
Genomic profiling and data interpretation for precision oncology
About OncoDNA
OncoDNA represents a paradigmatic shift in oncology—moving from symptom-based therapy to molecularly-informed, individualized medicine. The OncoDNA Group delivers a fully integrated precision oncology platform combining comprehensive genomic profiling (OncoDEEP® Kit: 638 genes, 1.8 Mb coverage), proprietary interpretation software (OncoKDM® platform trained on 3M+ variants, 600+ drugs, 2K+ trials), and patient-centric reporting (OncoSHARE). The company operates as a federated European group (Belgium HQ, France sequencing infrastructure, Spain market expansion), employing 100+ professionals and working with 35+ distributors across 200+ institutions in 50 countries. Recent partnerships with Gustave Roussy, Institut Curie, and the €10M Moncodaneum initiative connecting 50 cancer centers signal traction in building European infrastructure for precision oncology.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2012
- Headquarters
- Charleroi, Belgium
- Employees
- 47
- Open positions
- 1
- Dealroom signal
- 71.7/100
- Industry
- Health
- Sub-industry
- BioTechnology, Health Platform
- Sector
- Biotech & Life Sciences, Data Analytics, Biotechnology, Oncology, Genetics and genomics, Molecular Biology, Precision Medicine, Health Diagnostics, Sustainable Development Goals
- Technology
- Hardware
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES C✓Equity / VC | Jul 2023 | $7.1M | $103M | Undisclosed | ↗ |
| SERIES B✓Equity / VC | Feb 2020 | $21M | $82M | Vesalius Biocapital Partners · SFPIM · Verve Ventures · Sambrinvest | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for OncoDNA is 4.1K monthly website visits, up 215.4% over the last three months. OncoDNA's team grew 0% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Ackermans & van Haaren
Vesalius Biocapital Partners
Swisscanto Invest
SFPIM
Verve Ventures
Sambrinvest
Other known investors3 additional known investors
Inventures Investment Partners
Wallonie Entreprendre
WE Venture
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about OncoDNA on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See OncoDNA’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.